| Name | Title | Contact Details |
|---|
Community Hospital Corporation owns, manages and consults with hospitals through three distinct organizations — CHC Hospitals, CHC Consulting and CHC ContinueCARE, which share a common purpose to guide, support and enhance the mission of community hospitals and healthcare providers.
Holmusk is a data science and health technology company dedicated to establishing objective evidence as a core utility to the treatment of mental health and chronic diseases. Founded in 2015, Holmusk is headquartered in Singapore with offices in North Carolina, New York City, London, Malaysia and Shanghai. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and is part of the Innovations in Healthcare’s 2020 Innovator Cohort. Holmusk`s vision is to build the world`s largest Real-World Evidence (RWE) platform and enable a leapfrog-change in research and the provision of care through machine learning, deep learning and digital tools. Holmusk’s proprietary technology is harnessed to analyze real-world data and drive data-driven medicine.
Complete Medical Communications is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Boas Surgical Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Allentown, PA. To find more information about Boas Surgical Inc, please visit www.boassurgical.com
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.